Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

Research output: Contribution to journalJournal articlepeer-review

Standard

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. / Kristensen, Gitte; Røder, Martin Andreas; Berg, Kasper Drimer; Elversang, Johanna; Iglesias-Gato, Diego; Moreira, José; Toft, Birgitte Grønkær; Brasso, Klaus.

In: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, Vol. 126, No. 10, 2018, p. 804-813.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Kristensen, G, Røder, MA, Berg, KD, Elversang, J, Iglesias-Gato, D, Moreira, J, Toft, BG & Brasso, K 2018, 'Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer', A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 126, no. 10, pp. 804-813. https://doi.org/10.1111/apm.12886

APA

Kristensen, G., Røder, M. A., Berg, K. D., Elversang, J., Iglesias-Gato, D., Moreira, J., Toft, B. G., & Brasso, K. (2018). Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, 126(10), 804-813. https://doi.org/10.1111/apm.12886

Vancouver

Kristensen G, Røder MA, Berg KD, Elversang J, Iglesias-Gato D, Moreira J et al. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2018;126(10):804-813. https://doi.org/10.1111/apm.12886

Author

Kristensen, Gitte ; Røder, Martin Andreas ; Berg, Kasper Drimer ; Elversang, Johanna ; Iglesias-Gato, Diego ; Moreira, José ; Toft, Birgitte Grønkær ; Brasso, Klaus. / Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. In: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2018 ; Vol. 126, No. 10. pp. 804-813.

Bibtex

@article{8be3375a0e16451788d4c67994dd4e6b,
title = "Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer",
abstract = "This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.",
keywords = "ERG, predictive biomarkers, pro-NPY, prostate cancer, radical prostatectomy",
author = "Gitte Kristensen and R{\o}der, {Martin Andreas} and Berg, {Kasper Drimer} and Johanna Elversang and Diego Iglesias-Gato and Jos{\'e} Moreira and Toft, {Birgitte Gr{\o}nk{\ae}r} and Klaus Brasso",
year = "2018",
doi = "10.1111/apm.12886",
language = "English",
volume = "126",
pages = "804--813",
journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",
issn = "0903-4641",
publisher = "Wiley Online",
number = "10",

}

RIS

TY - JOUR

T1 - Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

AU - Kristensen, Gitte

AU - Røder, Martin Andreas

AU - Berg, Kasper Drimer

AU - Elversang, Johanna

AU - Iglesias-Gato, Diego

AU - Moreira, José

AU - Toft, Birgitte Grønkær

AU - Brasso, Klaus

PY - 2018

Y1 - 2018

N2 - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

AB - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7–13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6–1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

KW - ERG

KW - predictive biomarkers

KW - pro-NPY

KW - prostate cancer

KW - radical prostatectomy

U2 - 10.1111/apm.12886

DO - 10.1111/apm.12886

M3 - Journal article

C2 - 30191621

AN - SCOPUS:85052934413

VL - 126

SP - 804

EP - 813

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 10

ER -

ID: 202983161